Clinical effect of transcatheter arterial chemoembolization combined with microwave ablation versus repeat resection in treatment of recurrent hepatocellular carcinoma

Jun LING; Wenwu WAN; Zheng ZENG; Huihua YAO; Ou JIANG; Bing DING

doi:10.3969/j.issn.1001-5256.2022.09.020

Volume 38 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(9): 2053-2060

PDF( 3683 KB)

Clinical effect of transcatheter arterial chemoembolization combined with microwave ablation versus repeat resection in treatment of recurrent hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.09.020

Jun LING¹,
Wenwu WAN^{1, 2},
Zheng ZENG^{1, 2},
Huihua YAO³,
Ou JIANG¹,
Bing DING^{1
,
,
,}

1.
The Second People's Hospital of Neijiang, Neijiang, Sichuan 641000, China
2.
School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China
3.
Department of Hepatobiliary Surgery, Chengdu First People's Hospital, Chengdu 610000, China

Research funding:

Major National Science and Technology Projects (2018ZX09303-014);

Scientific Research Project Plan of Sichuan Medical Association (S20062)

More Information

Corresponding author: DING Bing, scdingbing@sina.com(ORCID: 0000-0003-4432-9599)
Received Date: 2022-01-12
Accepted Date: 2022-02-15
Published Date: 2022-09-20

Abstract

Abstract

Objective To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with microwave ablation (MWA) (TACE-MWA) versus repeat resection (RR) in the treatment of recurrent hepatocellular carcinoma (RHCC). Methods A total of 178 patients with RHCC who were admitted to The Second People's Hospital of Neijiang from June 2015 to September 2020 were enrolled, and according to the treatment modality, they were divided into RR group with 64 patients and TACE-MWA group with 114 patients. Baseline demographic data, liver function, and tumor conditions before treatment were recorded, and the patients were followed up to October 2021 to compare postoperative overall survival (OS) time and recurrence-free survival (RFS) time between the two groups. Subgroup analysis based on recurrence pattern (recurrence time and tumor size) was performed, and the influencing factors for prognosis were analyzed. The independent samples t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data; the Kaplan-Meier method was used for postoperative survival rate, the Log-rank test was used for survival difference analysis, and a multivariate Cox regression analysis was used to investigate independent risk factors for survival. Results The multivariate analysis showed that tumor diameter, alpha-fetoprotein (AFP) level, alanine aminotransferase, albumin, and time to recurrence were independent prognostic factors for OS (all P < 0.05), and AFP level and time to recurrence were independent prognostic factors for RFS (both P < 0.05). For RHCC with late recurrence (> 2 years), there were significant differences between the two groups in median OS (54.0 months vs 36.0 months, χ²=6.171, P=0.013) and median RFS (28.0 months vs 21.0 months, χ²= 5.211, P=0.022). For RHCC with a tumor diameter of ≤5 cm, there was a significant difference in median OS between the two groups (33.0 months vs 27.0 months, χ²=6.447, P=0.011). Conclusion RR has a similar clinical effect to TACE-MWA in RHCC with early recurrence or a tumor diameter of > 5 cm, but RR should be the first choice for RHCC with late recurrence or a tumor diameter of ≤5 cm.
- Carcinoma, Hepatocellular,
- Chemoembolization, Therapeutic,
- Ablation Techniques,
- Hepatectomy

FullText(HTML)

References(31)

References

[1]	LURJE I, CZIGANY Z, BEDNARSCH J, et al. Treatment strategies for hepatocellular carcinoma—a multidisciplinary approach[J]. Int J Mol Sci, 2019, 20(6): 1465. DOI: 10.3390/ijms20061465.
[2]	TAKEISHI K, MAEDA T, TSUJITA E, et al. Predictors of intrahepatic multiple recurrences after curative hepatectomy for hepatocellular carcinoma[J]. Anticancer Res, 2015, 35(5): 3061-3066. https://kyushu-u.pure.elsevier.com/en/publications/predictors-of-intrahepatic-multiple-recurrences-after-curative-he
[3]	GUPTA S, KHAN S, KAWKA M, et al. Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(10): 1159-1167. DOI: 10.1080/17474124.2021.1967144.
[4]	ZHENG J, CAI J, TAO L, et al. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis[J]. Int J Surg, 2020, 83: 196-204. DOI: 10.1016/j.ijsu.2020.09.031.
[5]	RIZZO A, RICCI AD, BRANDI G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy[J]. Future Oncol, 2021, 17(7): 755-757. DOI: 10.2217/fon-2020-0986.
[6]	WANG X, LIANG H, LU Z. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation[J]. Minim Invasive Ther Allied Technol, 2020, 29(6): 344-352. DOI: 10.1080/13645706.2019.1649286.
[7]	JIN YJ, LEE JW, LEE OH, et al. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion[J]. J Gastroenterol Hepatol, 2014, 29(5): 1056-1064. DOI: 10.1111/jgh.12507.
[8]	TUNG-PING POON R, FAN ST, WONG J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma[J]. Ann Surg, 2000, 232(1): 10-24. DOI: 10.1097/00000658-200007000-00003.
[9]	PENG ZW, ZHANG YJ, LIANG HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial[J]. Radiology, 2012, 262(2): 689-700. DOI: 10.1148/radiol.11110637.
[10]	European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. Eur J Cancer, 2012, 48(5): 599-641. DOI: 10.1016/j.ejca.2011.12.021.
[11]	HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380. DOI: 10.1002/hep.29086.
[12]	EISENHAUER EA, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.
[13]	DINDO D, DEMARTINES N, CLAVIEN PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey[J]. Ann Surg, 2004, 240(2): 205-213. DOI: 10.1097/01.sla.0000133083.54934.ae.
[14]	CHO JY, HAN HS, CHOI Y, et al. Association of remnant liver ischemia with early recurrence and poor survival after liver resection in patients with hepatocellular carcinoma[J]. JAMA Surg, 2017, 152(4): 386-392. DOI: 10.1001/jamasurg.2016.5040.
[15]	CALDERARO J, PETITPREZ F, BECHT E, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma[J]. J Hepatol, 2019, 70(1): 58-65. DOI: 10.1016/j.jhep.2018.09.003.
[16]	JUNG SM, KIM JM, CHOI GS, et al. Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma[J]. J Gastrointest Surg, 2019, 23(2): 304-311. DOI: 10.1007/s11605-018-3927-2.
[17]	ZHANG X, LI C, WEN T, et al. Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern[J]. Eur J Gastroenterol Hepatol, 2015, 27(8): 933-940. DOI: 10.1097/MEG.0000000000000383.
[18]	PENG Z, CHEN S, WEI M, et al. Advanced recurrent hepatocellular carcinoma: Treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation[J]. Radiology, 2018, 287(2): 705-714. DOI: 10.1148/radiol.2018171541.
[19]	LIU Y, REN Y, GE S, et al. Transarterial chemoembolization in treatment-naïve and recurrent hepatocellular carcinoma: a propensity-matched outcome and risk signature analysis[J]. Front Oncol, 2021, 11: 662408. DOI: 10.3389/fonc.2021.662408.
[20]	TANG C, SHEN J, FENG W, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization for unresectable hepatocellular carcinoma: A retrospective study[J]. Medicine (Baltimore), 2016, 95(20): e3754. DOI: 10.1097/MD.0000000000003754.
[21]	YUAN W, YANG MJ, XU J, et al. Radiofrequency ablation combined with transarterial chemoembolization for specially located small hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2018, 17: 1533033818788529. DOI: 10.1177/1533033818788529.
[22]	YAN L, REN Y, QIAN K, et al. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study[J]. BMC Gastroenterol, 2021, 21(1): 182. DOI: 10.1186/s12876-021-01765-x.
[23]	HASSANIN TM, FOUAD Y, HASSNINE A, et al. Quality of life after transcatheter arterial chemoembolization combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma compared with transcatheter arterial chemoembolization alone[J]. Asian Pac J Cancer Prev, 2021, 22(4): 1255-1261. DOI: 10.31557/APJCP.2021.22.4.1255.
[24]	JIANG C, CHENG G, LIAO M, et al. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis[J]. World J Surg Oncol, 2021, 19(1): 81. DOI: 10.1186/s12957-021-02188-4.
[25]	MATSUDA M, FUJⅡ H, KONO H, et al. Surgical treatment of recurrent hepatocellular carcinoma based on the mode of recurrence: repeat hepatic resection or ablation are good choices for patients with recurrent multicentric cancer[J]. J Hepatobiliary Pancreat Surg, 2001, 8(4): 353-359. DOI: 10.1007/s005340170008.
[26]	HUANG ZY, LIANG BY, XIONG M, et al. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China[J]. Ann Surg Oncol, 2012, 19(8): 2515-2525. DOI: 10.1245/s10434-012-2269-7.
[27]	ZHENG X, REN Y, HU H, et al. Transarterial chemoembolization combined with radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma after curative resection: A 10-year single-center comparative study[J]. Front Oncol, 2021, 11: 713432. DOI: 10.3389/fonc.2021.713432.
[28]	BRUIX J, TAKAYAMA T, MAZZAFERRO V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2015, 16(13): 1344-1354. DOI: 10.1016/S1470-2045(15)00198-9.
[29]	LUO P, WU S, YU Y, et al. Current status and perspective biomarkers in AFP negative HCC: Towards screening for and diagnosing hepatocellular carcinoma at an earlier stage[J]. Pathol Oncol Res, 2020, 26(2): 599-603. DOI: 10.1007/s12253-019-00585-5.
[30]	ZHENG Y, ZHU M, LI M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2020, 146(10): 2439-2446. DOI: 10.1007/s00432-020-03331-6.
[31]	CHEN ZH, ZHANG XP, ZHOU TF, et al. Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis[J]. Eur J Surg Oncol, 2019, 45(11): 2188-2196. DOI: 10.1016/j.ejso.2019.06.031.

Relative Articles

[1]	Long HAI, Lina MA, Xia LUO, Xiangchun DING. Effect of miRNA-933 on the apoptosis and proliferation of LX-2 cells and its molecular mechanism[J]. Journal of Clinical Hepatology, 2024, 40(7): 1382-1389. doi: 10.12449/JCH240716
[2]	Yao ZHANG, Kai ZHANG, Pengdong KANG, Chao MA. Research advances in microRNA-200c in pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(4): 961-964. doi: 10.3969/j.issn.1001-5256.2022.04.045
[3]	Sheng CHEN, Guoxiang CHEN, Zhongming HE, Shujie CHENG, Jisen ZHAO. Role of miRNA in the development and progression of cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2021, 37(9): 2241-2245. doi: 10.3969/j.issn.1001-5256.2021.09.048
[4]	Huijun XIE, Nasot Rashed, Yong NING, Chuan GAO. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 448-451. doi: 10.3969/j.issn.1001-5256.2021.02.042
[5]	Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
[6]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[7]	Wu Jie, Li JingTao, Wei HaiLiang, Yan ShuGuang, Fan Yu, Guo YingJun, Chang ZhanJie. Advances in the role of microRNA in the intervention of malignant transformation of precancerous lesions of the liver by regulating the activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2020, 36(7): 1650-1654. doi: 10.3969/j.issn.1001-5256.2020.07.045
[8]	Guo Xuan, Tan Wei, Wang ChangJun. Mechanism of action of circular RNAs in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2340-2343. doi: 10.3969/j.issn.1001-5256.2020.10.039
[9]	Cheng YaFei, Wang Bin, Wang ShiMing. Role of microRNAs in gallbladder carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1900-1904. doi: 10.3969/j.issn.1001-5256.2020.08.049
[10]	Wang ZeXin, Guan LiJun, Li JianMing, Wang ZhiChao, Xue MengRuo, Qin XiaoJun. Effect of targeted regulation of the Wnt2 gene by microRNA( microRNA-21) on the proliferation and migration of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 803-807. doi: 10.3969/j.issn.1001-5256.2020.04.019
[11]	Wu JunYi, Lai ZhiDe, Tian YiFeng, Wang YaoDong. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1768-1772. doi: 10.3969/j.issn.1001-5256.2020.08.018
[12]	Huang XiangJun, Zhang WenXing. Expression features and clinical significance of the microRNA-888 gene family in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 119-122. doi: 10.3969/j.issn.1001-5256.2019.01.022
[13]	Niu YaQian, Chang YuLing, Liu Fang, Zhao Chuan, Chen Che. Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(9): 2082-2084. doi: 10.3969/j.issn.1001-5256.2019.09.044
[14]	Zhang ZhuQing, Lu ShuMing, Wang HuaLi, Xu MengYao, Li ChunYan, Xin Yue, Zhao JunJun. Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(8): 1502-1505. doi: 10.3969/j.issn.1001-5256.2017.08.018
[15]	Wang DongXu, Huo TingTing, Tian YaoWen, Zhao Lei. Current status of research on microRNA associated with colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2387-2390. doi: 10.3969/j.issn.1001-5256.2016.12.034
[16]	Qiu Hua, Sun XueHua, Zhou ZhenHua, Li Man, Zhang Xin, Gao YueQiu. Influence of interaction between endogenous miRNAs and hepatitis B virus in hepatocytes on hepatitis B virus transcription and related mechanisms[J]. Journal of Clinical Hepatology, 2016, 32(11): 2186-2190. doi: 10.3969/j.issn.1001-5256.2016.11.042
[17]	Xiao ZuoHan, Meng Gang, Wang LiZhi, Sun WenJin. Diagnostic value of combined determination of DNA ploidy level and miRNA-21 expression in ascites cells for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(1): 93-98. doi: 10.3969/j.issn.1001-5256.2015.01.020
[18]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
[19]	Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008
[20]	Guo JinSheng. Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy [J]. Journal of Clinical Hepatology, 2013, 29(5): 324-326.

Supplements(0)

Cited By

Cited by

Periodical cited type(1)

孙巍，丁晓燕，陈京龙，李文东，郭晓笛，申燕军，滕颖，刘晓民，魏建莹. MicroRNA-520a通过失活AKT抑制HepG2.2.15细胞中HBV DNA复制. 中国肝脏病杂志(电子版). 2018(04): 73-78 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(5) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (561) PDF downloads(67)

Clinical effect of transcatheter arterial chemoembolization combined with microwave ablation versus repeat resection in treatment of recurrent hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.09.020